Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic (mycophenolate sodium) graded dose escalation pharmacokinetics in the first 3 months after renal transplantation
2008-006072-30Phase 4Active
- Sponsor
- CHU Saint-Etienne
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in immunocompromise, sponsored by CHU Saint-Etienne. Primary endpoints: MPA AUC0-12h, MPAG AUC0-12h and 2 more. Started Mar 2009; status: active.
02
Drugs
mycophenolate sodium
03
Conditions
immunocompromise
Beyond the preview
Go deeper on 2008-006072-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006072-30.